[EN] CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE LA CÉRAMIDE GALACTOSYLTRANSFÉRASE POUR LE TRAITEMENT DE MALADIES
申请人:BIOMARIN PHARM INC
公开号:WO2017214505A1
公开(公告)日:2017-12-14
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.
Catalytic Oxidative Carbonylation of Arylamines to Ureas with W(CO)6/I2 as Catalyst
作者:Li Zhang、Ampofo K. Darko、Jennifer I. Johns、Lisa McElwee-White
DOI:10.1002/ejoc.201100657
日期:2011.11
was carried out by using W(CO)6 as the catalyst, I2 as the oxidant, CO as the carbonyl source and 4-(dimethylamino)pyridine (DMAP) as base. The reaction conditions were optimized with respect to different bases, molar ratio of DMAP/iodine, temperature, time, and CO pressure. Various p-substituted arylamines can be converted into the respective symmetrical and unsymmetrical N,N′-disubstituted ureas in
The potential catalytic activity of selected C,N‐chelated organotin(IV) compounds (e.g. halides and trifluoroacetates) for derivatization of both dimethyl carbonate (DMC) and diethyl carbonate (DEC) was investigated. Some tri‐, di‐ and monoorganotin(IV) species (LCN(n‐Bu)2SnCl (1), LCN(n‐Bu)2SnCl.HCl (1a), LCN(n‐Bu)2SnI (2), LCNPh2SnCl (3), LCNPh2SnI (4), LCN(n‐Bu)SnCl2 (5), LCNSnBr3 (6) and [LCNS
Zinc Powder Catalysed Formylation and Urealation of Amines Using
<scp>
CO
<sub>2</sub>
</scp>
as a
<scp>C1</scp>
Building Block
<sup>†</sup>
作者:Chongyang Du、Yaofeng Chen
DOI:10.1002/cjoc.202000072
日期:2020.10
valuable organiccompounds catalysed by cheap and biocompatible metal catalysts is one of important topics of current organic synthesis and catalysis. Herein, we report the zinc powder catalysed formylation and urealation of amines with CO2 and (EtO)3SiH under solvent free condition. Using 2 mol% zinc powder as the catalyst, a series of secondary amines, both the aromatic ones and the aliphatic ones,
Synthesis and Activity of 1,3,5-Triphenylimidazolidine-2,4-diones and 1,3,5-Triphenyl-2-thioxoimidazolidin-4-ones: Characterization of New CB<sub>1</sub> Cannabinoid Receptor Inverse Agonists/Antagonists
作者:Giulio G. Muccioli、Johan Wouters、Caroline Charlier、Gerhard K. E. Scriba、Teresa Pizza、Pierluigi Di Pace、Paolo De Martino、Wolfgang Poppitz、Jacques H. Poupaert、Didier M. Lambert
DOI:10.1021/jm050484f
日期:2006.2.1
affinity and selectivity for the human CB(1) cannabinoid receptor. A [(35)S]-GTPgammaS binding assay revealed the inverseagonist properties of the compounds at the CB(1) cannabinoid receptor. Furthermore, molecular modeling studies were conducted in order to delineate the binding mode of this series of derivatives into the CB(1) cannabinoid receptor. 1,3-Bis(4-bromophenyl)-5-phenylimidazolidine-2,4-dione